GLPBio

FT827

Catalog No.: GC32917Purity:>98.50%
COASDSData Sheet
FT827 is a selective, covalent ubiquitin-specific protease 7 (USP7; Ki=4.2µM, Kd=7.8µM) inhibitor.

Products are for research use only. Not for human use. We do not sell to patients.

FT827
Cas No.: 1959537-86-0
1mgIn Stock
$177.00
1
5mgIn Stock
$420.00
1
10mgIn Stock
$513.00
1
25mgIn Stock
$672.00
1
50mgIn Stock
$828.00
1
100mgIn Stock
$1,090.00
1
200mgIn Stock
$1,480.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Citations

No citations are currently available for this product. Below are selected publications citing GlpBio products.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

FT827 is a selective, covalent ubiquitin-specific protease 7 (USP7; Ki=4.2µM, Kd=7.8µM) inhibitor. FT827 can be used in cancer-related research[1-2].

In vitro, FT827 (0.1-2µM) treated MCF7 breast cancer cells for 60 minutes. FT827 specifically inhibited USP7 activity in cells and did not affect other DUBs including USP47 and USP10[2].

References:
[1] El-Hamaky AA, El-Hamamsy MH, El-Moselhy TF, et al. Therapeutic targeting of ubiquitin-specific protease 7 (USP7): Mechanistic insights, dysregulation, and advances in drug discovery. Eur J Med Chem. 2025 Oct 15;296:117872.
[2] Turnbull AP, Ioannidis S, Krajewski WW, et al. Molecular basis of USP7 inhibition by selective small-molecule inhibitors. Nature. 2017 Oct 26;550(7677):481-486.

Protocol

Cell experiment [1]:

Cell lines

MCF7 cells (human breast cancer cell line)

Preparation Method

Intact MCF7 breast cancer cells were incubated with FT827, followed by incubation with the ubiquitin active site suicide probe haemagglutinin (HA)-tagged ubiquitin bromoethyl (HA-UbC2Br).

Reaction Conditions

0.1μM; 60min

Applications

FT827 inhibited USP7 probe reactivity with IC50 of 0.1-2µM. FT827 only affected USP7, but not other deubiquitinases (DUBs) including USP47 and USP10

References:
[1] Turnbull AP, Ioannidis S, Krajewski WW, et al. Molecular basis of USP7 inhibition by selective small-molecule inhibitors. Nature. 2017 Oct 26;550(7677):481-486.

Product Documents

Purity:>98.50%Appearance:A solid
COASDSData Sheet

Chemical Properties

CAS No.
1959537-86-0
SMILES
C=CS(=O)(NC1=CC=CC=C1C2=CC=C(C(N3CCC(O)(CN(C=NC4=C5C=NN4C)C5=O)CC3)=O)C=C2)=O
Molecular Formula
C27H28N6O5S
Molecular Weight
548.61
Solubility
DMSO : 125 mg/mL (227.85 mM)
Storage
Store at -20°C
General tips
Select a suitable solvent according to the product solubility data. Once prepared, aliquot the stock solution to avoid repeated freeze-thaw cycles.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.

CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility

g/mol

Reviews

Review for FT827

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%